FDA Tracker

Phase 3 Clinical Trials With Primary Completion Dates in June 2026

Joseph Lee — Mon, 01 Jun 2026 11:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in June 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
ARDX	Ardelyx, Inc.	2026-06-01	Phase 3	NCT05643534	Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
BVNRY	Bavarian Nordic A/S	2026-06-01	Phase 3	NCT06844500	Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
BZYR	Burzynski Research Institute, Inc.	2026-06-01	Phase 3	NCT02887040	Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
CGON	CG Oncology, Inc.	2026-06-01	Phase 3	NCT06111235	A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
GNLX	Genelux Corporation	2026-06-01	Phase 3	NCT05281471	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
PRAX	Praxis Precision Medicines, Inc.	2026-06-01	Phase 3	NCT07019922	A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
RCUS	Arcus Biosciences, Inc.	2026-06-01	Phase 3	NCT05568095	A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
REGMF	RemeGen Co., Ltd.	2026-06-01	Phase 3	NCT05885503	Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
REGMF	RemeGen Co., Ltd.	2026-06-01	Phase 3	NCT05799287	A Study of Telitacicept for IgA Nephropathy (TELIGAN)
RNXT	RenovoRx, Inc.	2026-06-01	Phase 3	NCT03257033	Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
SNPHY	Santen Pharmaceutical Co., Ltd.	2026-06-01	Phase 3	NCT06683651	A Study in Chinese Patients With Acquired Blepharoptosis
TLX	Telix Pharmaceuticals Limited	2026-06-01	Phase 3	NCT07052214	PSMA PET Combined With MRI for the Detection of PCa
VNDA	Vanda Pharmaceuticals Inc.	2026-06-01	Phase 3	NCT04652882	Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

Phase 3 Clinical Trials With Primary Completion Dates in May 2026

Joseph Lee — Fri, 01 May 2026 11:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in May 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
DFTX	Definium Therapeutics, Inc.	2026-05-01	Phase 3	NCT06741228	A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
GRFS	Grifols, S.A.	2026-05-01	Phase 3	NCT05645107	A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
INCPF	InnoCare Pharma Limited	2026-05-01	Phase 3	NCT06842199	Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NMRA	Neumora Therapeutics, Inc.	2026-05-01	Phase 3	NCT06058013	Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NMRA	Neumora Therapeutics, Inc.	2026-05-01	Phase 3	NCT06058039	Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
OPHLY	Ono Pharmaceutical Co., Ltd.	2026-05-01	Phase 3	NCT05144854	A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 3 Clinical Trials With Primary Completion Dates in April 2026

Joseph Lee — Wed, 01 Apr 2026 11:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in April 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
HRMY	Harmony Biosciences Holdings, Inc.	2026-04-01	Phase 3	NCT04462770	A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NTLA	Intellia Therapeutics, Inc.	2026-04-01	Phase 3	NCT06634420	HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
OCS	Oculis Holding AG	2026-04-01	Phase 3	NCT06172257	A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
PTGX	Protagonist Therapeutics, Inc.	2026-04-01	Phase 3	NCT06033586	Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
VRDN	Viridian Therapeutics, Inc.	2026-04-01	Phase 3	NCT06812325	A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
VRDN	Viridian Therapeutics, Inc.	2026-04-01	Phase 3	NCT06625398	An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
VTGN	Vistagen Therapeutics, Inc.	2026-04-01	Phase 3	NCT06615557	Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
ZLDPF	Zealand Pharma A/S	2026-04-01	Phase 3	NCT03905707	Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ZLDPF	Zealand Pharma A/S	2026-04-01	Phase 3	NCT04881825	Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Phase 3 Clinical Trials With Primary Completion Dates in March 2026

Joseph Lee — Sun, 01 Mar 2026 12:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in March 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
AARD	Aardvark Therapeutics, Inc.	2026-03-01	Phase 3	NCT06828861	ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
ALMRY	Almirall SA	2026-03-01	Phase 3	NCT05916365	Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
AMLX	Amylyx Pharmaceuticals, Inc.	2026-03-01	Phase 3	NCT06747468	Avexitide for Treatment of Post-Bariatric Hypoglycemia
CING	Cingulate Inc.	2026-03-01	Phase 3	NCT05924594	Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
IMVT	Immunovant, Inc.	2026-03-01	Phase 3	NCT05524571	Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
IVVD	Invivyd, Inc.	2026-03-01	Phase 3	NCT07298434	Study of VYD2311 for the Prevention of COVID-19
KPTI	Karyopharm Therapeutics Inc.	2026-03-01	Phase 3	NCT05028348	A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
KPTI	Karyopharm Therapeutics Inc.	2026-03-01	Phase 3	NCT04562389	Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
VRDN	Viridian Therapeutics, Inc.	2026-03-01	Phase 3	NCT06625411	An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Phase 3 Clinical Trials With Primary Completion Dates in February 2026

Joseph Lee — Sun, 01 Feb 2026 12:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in February 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
ARDX	Ardelyx, Inc.	2026-02-01	Phase 3	NCT06810167	Assessing Tenapanor as a Treatment of CF-related Constipation.
CANF	Can-Fite BioPharma Ltd.	2026-02-01	Phase 3	NCT05201404	Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
DAWN	Day One Biopharmaceuticals, Inc.	2026-02-01	Phase 3	NCT05566795	DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
KOD	Kodiak Sciences Inc.	2026-02-01	Phase 3	NCT06990399	A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NMRA	Neumora Therapeutics, Inc.	2026-02-01	Phase 3	NCT06058039	Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
PHVS	Pharvaris N.V.	2026-02-01	Phase 3	NCT05834777	Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

Phase 3 Clinical Trials With Primary Completion Dates in January 2026

Joseph Lee — Thu, 01 Jan 2026 12:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in January 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
ADCT	ADC Therapeutics SA	2026-01-01	Phase 3	NCT04384484	Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
BCTX	BriaCell Therapeutics Corp.	2026-01-01	Phase 3	NCT06072612	Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
CASBF	CanSino Biologics Inc.	2026-01-01	Phase 3	NCT06857370	Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine
PVLA	Palvella Therapeutics, Inc.	2026-01-01	Phase 3	NCT06239480	SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
TBPH	Theravance Biopharma, Inc.	2026-01-01	Phase 3	NCT05696717	Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Phase 3 Clinical Trials With Primary Completion Dates in December 2025

Joseph Lee — Mon, 01 Dec 2025 12:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in December 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
ASPHF	Ascentage Pharma Group International	2025-12-01	Phase 3	NCT06423911	Study of Olverembatinib (HQP1351) in Patients With CP-CML
AVEFF	Avecho Biotechnology Limited	2025-12-01	Phase 3	NCT05840822	Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia
AXSM	Axsome Therapeutics, Inc.	2025-12-01	Phase 3	NCT06413433	Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
BVNRY	Bavarian Nordic A/S	2025-12-01	Phase 3	NCT06844487	Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
BVNRY	Bavarian Nordic A/S	2025-12-01	Phase 3	NCT06844500	Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
CLRPF	Clarity Pharmaceuticals Ltd	2025-12-01	Phase 3	NCT06056830	Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
CLVLY	Clinuvel Pharmaceuticals Limited	2025-12-01	Phase 3	NCT06109649	A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
IMVT	Immunovant, Inc.	2025-12-01	Phase 3	NCT05524571	Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
IMVT	Immunovant, Inc.	2025-12-01	Phase 3	NCT05517421	Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
MLYS	Mineralys Therapeutics, Inc.	2025-12-01	Phase 3	NCT05968430	Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
QNCX	Quince Therapeutics, Inc.	2025-12-01	Phase 3	NCT06193200	Evaluate the Neurological Effects of EryDex on Subjects With A-T
RYTM	Rhythm Pharmaceuticals, Inc.	2025-12-01	Phase 3	NCT05093634	EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
SLS	SELLAS Life Sciences Group, Inc.	2025-12-01	Phase 3	NCT04229979	Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
TVTX	Travere Therapeutics, Inc.	2025-12-01	Phase 3	NCT06247085	A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
VNDA	Vanda Pharmaceuticals Inc.	2025-12-01	Phase 3	NCT04652882	Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
VNDA	Vanda Pharmaceuticals Inc.	2025-12-01	Phase 3	NCT06836557	Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
XENE	Xenon Pharmaceuticals Inc.	2025-12-01	Phase 3	NCT05614063	A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
XFOR	X4 Pharmaceuticals, Inc.	2025-12-01	Phase 3	NCT03995108	Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Phase 3 Clinical Trials With Primary Completion Dates in November 2025

Joseph Lee — Sat, 01 Nov 2025 11:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in November 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
BBNX	Beta Bionics, Inc.	2025-11-01	Phase 3	NCT06449677	Bionic Pancreas in CFRD
BHVN	Biohaven Ltd.	2025-11-01	Phase 3	NCT04641143	Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
CZMWY	Carl Zeiss Meditec AG	2025-11-01	Phase 3	NCT02685605	Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
DBVT	DBV Technologies S.A.	2025-11-01	Phase 3	NCT05741476	Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
DBVTF	DBV TECHNOLOGIES	2025-11-01	Phase 3	NCT05741476	Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
GOSS	Gossamer Bio, Inc.	2025-11-01	Phase 3	NCT05934526	Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
TLX	Telix Pharmaceuticals Limited	2025-11-01	Phase 3	NCT04876651	The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Phase 3 Clinical Trials With Primary Completion Dates in October 2025

Joseph Lee — Wed, 01 Oct 2025 11:00:01 +0000

This is a list of Phase 3 trials with primary completion dates in October 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
ACAD	ACADIA Pharmaceuticals Inc.	2025-10-01	Phase 3	NCT06173531	Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
IBRX	ImmunityBio, Inc.	2025-10-01	Phase 3	NCT03520686	QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
NPPNY	Nippon Shinyaku Co., Ltd.	2025-10-01	Phase 3	NCT04768062	Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
REGMF	RemeGen Co., Ltd.	2025-10-01	Phase 3	NCT05799287	A Study of Telitacicept in Patients with Primary Immunoglobulin A（IgA） Nephropathy
SOLTF	Nxera Pharma Co., Ltd.	2025-10-01	Phase 3	NCT07028697	A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder
VTGN	Vistagen Therapeutics, Inc.	2025-10-01	Phase 3	NCT06358651	Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

Phase 3 Clinical Trials With Primary Completion Dates in September 2025

Joseph Lee — Mon, 01 Sep 2025 11:00:02 +0000

This is a list of Phase 3 trials with primary completion dates in September 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

Symbol	Company	Primary Completion Date	Phase	NCT ID	Title
ALEC	Alector, Inc.	2025-09-01	Phase 3	NCT04374136	A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
ALMS	Alumis Inc.	2025-09-01	Phase 3	NCT06586112	A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
ALMS	Alumis Inc.	2025-09-01	Phase 3	NCT06588738	A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
APLS	Apellis Pharmaceuticals, Inc.	2025-09-01	Phase 3	NCT04770545	An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
BFRI	Biofrontera Inc.	2025-09-01	Phase 3	NCT05662202	Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
GOSS	Gossamer Bio, Inc.	2025-09-01	Phase 3	NCT05934526	Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
HLBBF	H. Lundbeck A/S	2025-09-01	Phase 3	NCT05164172	A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
IONS	Ionis Pharmaceuticals, Inc.	2025-09-01	Phase 3	NCT04849741	A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
KPTI	Karyopharm Therapeutics Inc.	2025-09-01	Phase 3	NCT04562389	Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
OGN	Organon & Co.	2025-09-01	Phase 3	NCT06134479	Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.
ORGO	Organogenesis Holdings Inc.	2025-09-01	Phase 3	NCT06000410	A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee
SLS	SELLAS Life Sciences Group, Inc.	2025-09-01	Phase 3	NCT04229979	Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2